188 related articles for article (PubMed ID: 34910788)
61. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
[TBL] [Abstract][Full Text] [Related]
62. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
Araki M; Komatsu N
Cancer Sci; 2017 Oct; 108(10):1907-1912. PubMed ID: 28741795
[TBL] [Abstract][Full Text] [Related]
63. Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis.
Jeong JH; Lee HT; Seo JY; Seo YH; Kim KH; Kim MJ; Lee JH; Park J; Hong JS; Park PW; Ahn JY
Ann Lab Med; 2016 Jul; 36(4):291-9. PubMed ID: 27139600
[TBL] [Abstract][Full Text] [Related]
64. Aberrant Calreticulin Expression in Articular Cartilage of Dio2 Deficient Mice.
Bomer N; Cornelis FM; Ramos YF; den Hollander W; Lakenberg N; van der Breggen R; Storms L; Slagboom PE; Lories RJ; Meulenbelt I
PLoS One; 2016; 11(5):e0154999. PubMed ID: 27163789
[TBL] [Abstract][Full Text] [Related]
65. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
Wang J; Hao J; He N; Ji C; Ma D
Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
[TBL] [Abstract][Full Text] [Related]
66. Dexamethasone-Mediated Upregulation of Calreticulin Inhibits Primary Human Glioblastoma Dispersal Ex Vivo.
Nair M; Romero J; Mahtabfar A; Meleis AM; Foty RA; Corbett SA
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29443896
[TBL] [Abstract][Full Text] [Related]
67. Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy.
Liang Z; Wang X; Dong K; Li X; Qin C; Zhou H
Biomed Res Int; 2021; 2021():5575704. PubMed ID: 33977106
[TBL] [Abstract][Full Text] [Related]
68. The role of calreticulin mutations in myeloproliferative neoplasms.
Araki M; Komatsu N
Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
[TBL] [Abstract][Full Text] [Related]
69. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
70. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
[TBL] [Abstract][Full Text] [Related]
71. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
72. Correlation of zinc finger protein 2, a prognostic biomarker, with immune infiltrates in liver cancer.
Sun L; Lin Y; Wang G; Zhang L; Hu L; Lu Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33439969
[TBL] [Abstract][Full Text] [Related]
73. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
Araki M
Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
[TBL] [Abstract][Full Text] [Related]
74. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
75. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
76. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
Park SH; Kim SY; Lee SM; Yi J; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
Ann Lab Med; 2015 Mar; 35(2):233-7. PubMed ID: 25729726
[TBL] [Abstract][Full Text] [Related]
77. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
78. Mapping human calreticulin regions important for structural stability.
Čiplys E; Paškevičius T; Žitkus E; Bielskis J; Ražanskas R; Šneideris T; Smirnovas V; Kaupinis A; Tester DJ; Ackerman MJ; Højrup P; Michalak M; Houen G; Slibinskas R
Biochim Biophys Acta Proteins Proteom; 2021 Nov; 1869(11):140710. PubMed ID: 34358706
[TBL] [Abstract][Full Text] [Related]
79. Novel evidence of the involvement of calreticulin in major psychiatric disorders.
Ohadi M; Mirabzadeh A; Esmaeilzadeh-Gharehdaghi E; Rezazadeh M; Hosseinkhanni S; Oladnabi M; Firouzabadi SG; Darvish H
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jun; 37(2):276-81. PubMed ID: 22507216
[TBL] [Abstract][Full Text] [Related]
80. CALR mutation screening in pediatric primary myelofibrosis.
An W; Wan Y; Guo Y; Chen X; Ren Y; Zhang J; Chang L; Wei W; Zhang P; Zhu X
Pediatr Blood Cancer; 2014 Dec; 61(12):2256-62. PubMed ID: 25176567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
